Geode Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.8M Buy
655,785
+67,392
+11% +$1.51M ﹤0.01% 2238
2025
Q4
$21.4M Buy
588,393
+118,358
+25% +$3.89M ﹤0.01% 1963
2025
Q3
$10.4M Buy
470,035
+96,418
+26% +$1.57M ﹤0.01% 2393
2025
Q2
$3.62M Buy
373,617
+16,461
+5% +$160K ﹤0.01% 2894
2025
Q1
$2.82M Buy
357,156
+8,396
+2% +$65.7K ﹤0.01% 2919
2024
Q4
$2.86M Buy
348,760
+323,903
+1,303% +$5.05M ﹤0.01% 3009
2024
Q3
$421K Buy
+24,857
New +$447K ﹤0.01% 3658

Other funds holding ZBIO

Geode Capital Management's ZBIO Position: Q1 2026 in Review

Geode Capital Management increased its Zenas BioPharma (ZBIO) stake by 11% in Q1 2026, buying an estimated $1.51M and bringing the position to 655,785 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Geode Capital Management first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $21.4M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Geode Capital Management held 655,785 shares of Zenas BioPharma worth $12.8M as of Q1 2026.
  • Geode Capital Management bought 67,392 Zenas BioPharma shares in Q1 2026, an estimated $1.51M.
  • Zenas BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2238 holding.
  • Geode Capital Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
  • Geode Capital Management's Zenas BioPharma position peaked at $21.4M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.